ADELAIDE, Australia / RankWire.AI / – Australian researchers in the medical field have pinpointed a molecular switch that controls the dissemination of aggressive tumors, revealing a potential pathway for therapy aimed at preventing secondary cancers. The study, published in EMBO Molecular Medicine, involved scientists from Adelaide University and the Olivia Newton-John Cancer Research Institute. They demonstrated that restoring the levels of a crucial regulatory molecule called miR-342 significantly curtails tumor metastasis. These results indicate a promising new approach to combat triple-negative breast cancer by targeting dormant cancer cells before they cause dangerous lesions in distant organs.
Although triple-negative breast cancer accounts for 10% to 15% of the approximately 21,000 breast cancer cases diagnosed annually in Australia, it accounts for a disproportionate number of fatalities. This subtype lacks estrogen, progesterone, and HER2 receptors, which renders standard hormone-targeted therapies ineffective. The lead researchers showed that a decline in miR-342 levels leads to hyperactivation of a cancer-promoting pathway known as E2F. This activation allows dormant cancer cells to disseminate and generate perilous secondary tumors throughout the body.
Targeted Treatment Options Bring New Possibilities for Preventing High-Risk Metastasis
Using pre-clinical models, the scientists found that increasing miR-342 levels notably decreased the spread of cancer to distant sites. Moreover, they observed that palbociclib, an existing CDK4/6 inhibitor drug approved for hormone receptor-positive breast cancers, significantly impeded metastatic tumor growth in models showing low miR-342 expression. These findings suggest that assessing miR-342 levels could enable clinicians to repurpose current therapies to treat patients at high risk of metastasis.
Associate Professor Philip Gregory, co-senior author from Adelaide University’s Centre for Cancer Biology, confirmed that preventing metastasis remains the key challenge in managing aggressive breast cancers. He stressed that because palbociclib targets the overactive E2F pathway, administering it after cancer cells have spread prevents microscopic deposits from expanding. This approach shifts the focus from merely reducing primary tumor size to stopping microscopic secondary cancers from progressing into life-threatening conditions.
Peer-Reviewed Pre-Clinical Data Published in EMBO Molecular Medicine
The research team highlighted that the biological diversity of triple-negative breast cancer has historically posed difficulties in developing universal targeted treatments. By identifying a specific biological vulnerability shared among a subgroup of patients, the study paves the way for personalized therapy strategies. As Australian scientists continue to explore this promising approach, preparations are underway to validate these findings using patient-derived models in advance of clinical trials.
Cancer specialists and research organizations across Australia expressed optimism about the significance of these discoveries, emphasizing the urgent need for expanded treatment options when primary therapies do not succeed. The team intends to work with international clinical networks to speed up biomarker screening processes. Validating miR-342 testing could soon enable doctors to identify suitable candidates for targeted CDK4/6 inhibitor treatments early in the disease course.